Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

PP405 and JXL-069 are the same compound, but users experienced no results due to flawed application methods. The topical gel formulation of PP405 is designed to target hair follicle stem cells effectively, unlike liquid solutions that fail to penetrate deeply.

Taking 5mg oral minoxidil at night instead of splitting 2.5mg doses, with the rationale that a single larger dose may provide a stronger activation for hair follicles and reduce peak-related side effects. Some users report sleep issues with nighttime dosing, while others find it beneficial; opinions on effectiveness and side effects vary.

Finasteride is likely causing beard thinning due to its anti-androgen effects, which reduce DHT levels necessary for thick facial hair. Some users suggest using minoxidil to potentially counteract this effect, while others note that stopping finasteride may allow the beard to regrow.

Hair loss involves more than just DHT, with genetic factors like TRPS affecting hair follicles. Treatments such as Amplifica's AMP-601 and AMP-303 target stem cells for potential hair growth solutions.

The conversation humorously suggests that the hair loss industry, referred to as "Big Bald," deliberately delays a cure to profit from ongoing treatments like minoxidil, finasteride, and dutasteride. Participants debate whether a cure would be more profitable than current treatments, with some suggesting that the industry prefers continuous treatments for sustained profit.

Noticeable hair regrowth occurred after two months of using minoxidil and starting finasteride. Users suggested continuing the treatment and considering microneedling for better results.

Creatine does not significantly affect DHT levels or cause hair loss. Some users continue using finasteride and minoxidil while taking creatine, expressing skepticism about its impact on hair loss.

A user switched from finasteride to dutasteride and from topical to oral minoxidil, experiencing significant hair shedding. They plan to continue this regimen for a year before deciding on any changes.

PP-405, a potential hair loss treatment, shows promise in stimulating dormant hair follicles and may help with various hair loss types. Current treatments like Minoxidil are still recommended as PP-405 is in early trials and may take years to become available.

PP405 is a new hair loss treatment in phase 2 trials that may promote hair growth by increasing lactate production and activating hair follicle stem cells. It could potentially replace hormone-disrupting treatments like Minoxidil and finasteride.

Pelage PP405 is a new hair loss treatment in trials, potentially reactivating dormant hair follicles without affecting hormones. Results are expected in February 2025, offering an alternative to minoxidil and finasteride.

A 29-year-old male shares his 3-month hair regrowth progress using finasteride, minoxidil, and microneedling, reporting no side effects and light initial shedding. He is encouraged by the results and plans to continue the treatment.

Hair cloning is humorously discussed as always being 5-7 years away, with skepticism about its near-term availability. Gene editing to reactivate dormant follicles is suggested as a more likely solution within the next ten years.

A 29-year-old man has been using finasteride for 8 months but is still experiencing hair shedding and is considering adding minoxidil or switching to dutasteride. Users advise that shedding is normal, suggest continuing finasteride for a year, and recommend consulting a dermatologist before changing treatments.

A user has been using finasteride, minoxidil, and microneedling for hair loss but continues to experience thinning and has been rejected for a hair transplant due to a thin donor region. They are considering switching to dutasteride and exploring other treatments like mesotherapy, PRP, and topical anti-androgens, while also contemplating shaving their head.

The user has been using topical minoxidil for over 6 months and topical finasteride for 3 months without seeing significant progress and is considering stopping minoxidil. Other users suggest continuing the treatment for a longer period, as progress can take time, and recommend considering oral versions for potentially better results.

Hair loss may be influenced by mechanical tension and inflammation, with the hi-c5 protein amplifying androgen effects, leading to follicle miniaturization. Treatments like finasteride, minoxidil, and scalp massages are suggested to manage hair loss.

The user experienced significant hair growth using oral minoxidil and finasteride but started shedding after adding enclomiphene to improve athletic performance. They are seeking advice on managing the shedding while continuing the treatment.

Finasteride mainly prevents further hair loss by blocking DHT but doesn't reverse existing damage, while minoxidil can promote regrowth by waking dormant follicles. Ketoconazole helps with inflammation, but none of these treatments can reverse fibrosis or structural changes around hair follicles.

A 21-year-old is using oral dutasteride and topical minoxidil 5% to treat hair loss, noticing reduced shedding and new hair growth, especially around the hairline. They experience mood changes as a side effect of dutasteride and are hopeful about continued progress with this treatment combination.

RU58841 hasn't stopped shedding for the user after three weeks, despite being stable on dutasteride for six years. Suggestions include continuing RU58841 for 4-6 months, considering minoxidil, and addressing stress and sleep issues.

The user experienced hair regrowth with dutasteride and oral minoxidil from October 2025 to January 2026, but mid-scalp density decreased afterward despite continued treatment. Ketoconazole improves scalp condition, but stopping it worsens hair appearance.

PP405 is viewed skeptically, with some seeing it as overhyped and potentially ineffective compared to existing treatments like minoxidil and finasteride. While it shows some promise in activating dormant hair follicles, many believe it won't replace hair transplants or significantly outperform current options.

A 49-year-old is using minoxidil, finasteride, and supplement chews for hair growth, experiencing thick growth except on the top, and seeking advice on improving density. Suggestions include continuing treatment, considering additional options like oral minoxidil, ketoconazole shampoo, dermapen, and possibly a hair transplant, though cost is a concern.

The user shared their positive experience with hair regrowth using dutasteride, initially combined with minoxidil, noting significant improvement in hair thickness and hairline over 1.5 years. They stopped minoxidil due to its greasiness but continued with dutasteride every other day, experiencing manageable shedding and no serious side effects.

The conversation discusses hair loss treatment with finasteride, where the user is experiencing shedding and concerns about regrowth. Users advise patience, suggesting that visible improvement may take 6-12 months or longer, and recommend continuing the treatment.

A 46-year-old man is using minoxidil, finasteride, and derma rolling for hair regrowth but is unsure of the results and considering a hair transplant. Many suggest he looks good bald and recommend continuing treatment or trying scalp micropigmentation.

Breezula shows promising hair growth results, with up to 539% increase in hair count compared to placebo, and regulatory submissions are planned in the US and EU. Users are cautiously optimistic, noting the potential for Breezula to replace finasteride by targeting DHT without systemic effects.

Stopping finasteride and minoxidil can cause significant hair shedding, so they should be continued indefinitely. Concerns about finasteride affecting fertility or causing birth defects are mostly unfounded, but some stop for personal reasons.

The conversation discusses the potential updates on the pp405 trial for hair loss, with completion expected by December 2025. Participants express skepticism about new treatments, suggesting continued use of finasteride, while others hope for innovative solutions beyond current medications.